p.82 抽出テキスト
297. Friedland IR, McCracken GH Jr. Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. N Engl J Med 1994;331:377–382. https://doi.org/10.1056/NEJM199408113310607 298. van Ettekoven CN, van de Beek D, Brouwer MC. Update on community-acquired bacterial meningitis: guidance and challenges. Clin Microbiol Infect 2017;23:601–606. https://doi.org/10.1016/j.cmi.2017.04.019 299. Fernandez Hidalgo N, Gharamti AA, Aznar ML, Almirante B, Yasmin M, Fortes CQ, et al. Beta-hemolytic streptococcal infective endocarditis: characteristics and outcomes from a large, multinational cohort. Open Forum Infect Dis 2020;7:ofaa120. https://doi.org/10.1093/ofid/ofaa120 300. Lefort A, Lortholary O, Casassus P, Selton-Suty C, Guillevin L, Mainardi JL, et al. Comparison between adult endocarditis due to beta-hemolytic streptococci (serogroups A, B, C, and G) and Streptococcus milleri: a multicenter study in France. Arch Intern Med 2002;162:2450–2456. https://doi.org/10.1001/archinte.162.21.2450 301. Sambola A, Miro JM, Tornos MP, Almirante B, Moreno-Torrico A, Gurgui M, et al. Streptococcus agalactiae infective endocarditis: analysis of 30 cases and review of the literature, 1962–1998. Clin Infect Dis 2002;34:1576–1584. https://doi.org/10.1086/ 340538 302. Adam EL, Siciliano RF, Gualandro DM, Calderaro D, Issa VS, Rossi F, et al. Case series of infective endocarditis caused by Granulicatella species. Int J Infect Dis 2015;31:56–58. https://doi.org/10.1016/j.ijid.2014.10.023 303. Giuliano S, Caccese R, Carfagna P, Vena A, Falcone M, Venditti M. Endocarditis caused by nutritionally variant streptococci: a case report and literature review. Infez Med 2012;20:67–74. 304. Tellez A, Ambrosioni J, Hernandez-Meneses M, Llopis J, Ripa M, Chambers ST, et al. Clinical characteristics and outcome of infective endocarditis due to Abiotrophia and Granulicatella compared to Viridans group streptococci. J Infect 2022;85:137–146. https://doi.org/10.1016/j.jinf.2022.05.023 305. Fernandez-Hidalgo N, Ribera A, Larrosa MN, Viedma E, Origuen J, de Alarcon A, et al. Impact of Staphylococcus aureus phenotype and genotype on the clinical characteristics and outcome of infective endocarditis. A multicentre, longitudinal, prospective, observational study. Clin Microbiol Infect 2018;24:985–991. https://doi.org/10.1016/j.cmi. 2017.12.002 306. Sandoe JA, Kerr KG, Reynolds GW, Jain S. Staphylococcus capitis endocarditis: two cases and review of the literature. Heart 1999;82:e1. https://doi.org/10.1136/hrt.82. 3.e1 307. Cone LA, Sontz EM, Wilson JW, Mitruka SN. Staphylococcus capitis endocarditis due to a transvenous endocardial pacemaker infection: case report and review of Staphylococcus capitis endocarditis. Int J Infect Dis 2005;9:335–339. https://doi.org/10. 1016/j.ijid.2004.08.004 308. Korzeniowski O, Sande MA. Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts: a prospective study. Ann Intern Med 1982;97:496–503. https://doi.org/10.7326/0003-4819- 97-4-496 309. Apellaniz G, Valdes M, Perez R, Martin-Luengo F, Garcia A, Soria F, et al. [Teicoplanin versus cloxacillin, cloxacillin-gentamycin and vancomycin in the treatment of experimental endocarditis caused by methicillin-sensitive Staphylococcus aureus]. Enferm Infecc Microbiol Clin 1991;9:208–210. 310. Huang C, Chen I, Lin L. Comparing the outcomes of ceftaroline plus vancomycin or daptomycin combination therapy versus vancomycin or daptomycin monotherapy in adults with methicillin-resistant Staphylococcus aureus bacteremia–a meta-analysis. Antibiotics (Basel) 2022;11:1104. https://doi.org/10.3390/antibiotics11081104 311. Veliev A, Nakipoglu Y. Investigation of Staphylococcus lugdunensis and selected coagulase negative staphylococci isolated from blood culture bottles and determination of their sensitivities to antibiotics. Pak J Med Sci 2022;38:657–662. https://doi.org/10. 12669/pjms.38.3.4738 312. Chirouze C, Cabell CH, Fowler VG Jr, Khayat N, Olaison L, Miro JM, et al. Prognostic factors in 61 cases of Staphylococcus aureus prosthetic valve infective endocarditis from the International Collaboration on Endocarditis merged database. Clin Infect Dis 2004; 38:1323–1327. https://doi.org/10.1086/383035 313. Oberbach A, Schlichting N, Hagl C, Lehmann S, Kullnick Y, Friedrich M, et al. Four decades of experience of prosthetic valve endocarditis reflect a high variety of diverse pathogens. Cardiovasc Res 2023;119:410–428. https://doi.org/10.1093/cvr/cvac055 314. Hassoun A. Treatment of Staphylococcus aureus prosthetic valve endocarditis. Am J Med 2007;120:e9, author reply e11. https://doi.org/10.1016/j.amjmed.2006.02.021 315. Marin M, Munoz P, Sanchez M, Del Rosal M, Alcala L, Rodriguez-Creixems M, et al. Molecular diagnosis of infective endocarditis by real-time broad-range polymerase chain reaction (PCR) and sequencing directly from heart valve tissue. Medicine (Baltimore) 2007;86:195–202. https://doi.org/10.1097/MD.0b013e31811f44ec 316. Martinez-Selles M, Munoz P, Arnaiz A, Moreno M, Galvez J, Rodriguez-Roda J, et al. Valve surgery in active infective endocarditis: a simple score to predict in-hospital prognosis. Int J Cardiol 2014;175:133–137. https://doi.org/10.1016/j.ijcard.2014.04.266 317. Munoz P, Kestler M, De Alarcon A, Miro JM, Bermejo J, Rodriguez-Abella H, et al. Current epidemiology and outcome of infective endocarditis: a multicenter, prospective, cohort study. Medicine (Baltimore) 2015;94:e1816. https://doi.org/10.1097/MD. 0000000000001816 318. Saginur R, Stdenis M, Ferris W, Aaron SD, Chan F, Lee C, et al. Multiple combination bactericidal testing of staphylococcal biofilms from implant-associated infections. Antimicrob Agents Chemother 2006;50:55–61. https://doi.org/10.1128/AAC.50.1.55- 61.2006 319. Saeed K, Bal AM, Gould IM, David MZ, Dryden M, Giannitsioti E, et al. An update on Staphylococcus aureus infective endocarditis from the International Society of Antimicrobial Chemotherapy (ISAC). Int J Antimicrob Agents 2019;53:9–15. https:// doi.org/10.1016/j.ijantimicag.2018.09.014 320. Ramos-Martinez A, Munoz Serrano A, de Alarcon Gonzalez A, Munoz P, Fernandez-Cruz A, Valerio M, et al. Gentamicin may have no effect on mortality of staphylococcal prosthetic valve endocarditis. J Infect Chemother 2018;24:555–562. https://doi.org/10.1016/j.jiac.2018.03.003 321. Riedel DJ, Weekes E, Forrest GN. Addition of rifampin to standard therapy for treatment of native valve infective endocarditis caused by Staphylococcus aureus. Antimicrob Agents Chemother 2008;52:2463–2467. https://doi.org/10.1128/AAC.00300-08 322. Sader HS, Carvalhaes CG, Mendes RE. Ceftaroline activity against Staphylococcus aureus isolated from patients with infective endocarditis, worldwide (2010–2019). Int J Infect Dis 2021;102:524–528. https://doi.org/10.1016/j.ijid.2020.11.130 323. Zasowski EJ, Trinh TD, Claeys KC, Lagnf AM, Bhatia S, Klinker KP, et al. Multicenter cohort study of ceftaroline versus daptomycin for treatment of methicillin-resistant Staphylococcus aureus bloodstream infection. Open Forum Infect Dis 2022;9:ofab606. https://doi.org/10.1093/ofid/ofab606 324. Sader HS, Mendes RE, Pfaller MA, Flamm RK. Antimicrobial activity of dalbavancin tested against Gram-positive organisms isolated from patients with infective endocarditis in US and European medical centres. J Antimicrob Chemother 2019;74:1306–1310. https://doi.org/10.1093/jac/dkz006 325. Casapao AM, Davis SL, McRoberts JP, Lagnf AM, Patel S, Kullar R, et al. Evaluation of vancomycin population susceptibility analysis profile as a predictor of outcomes for patients with infective endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2014;58:4636–4641. https://doi.org/10.1128/AAC. 02820-13 326. Ishaq H, Tariq W, Talha KM, Palraj BRV, Sohail MR, Baddour LM, et al. Association between high vancomycin minimum inhibitory concentration and clinical outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: a meta-analysis. Infection 2021;49:803–811. https://doi.org/10.1007/s15010-020-01568-4 327. Maraolo AE, Giaccone A, Gentile I, Saracino A, Bavaro DF. Daptomycin versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus bloodstream infection with or without endocarditis: a systematic review and meta-analysis. Antibiotics (Basel) 2021;10:1014. https://doi.org/10.3390/antibiotics10081014 328. Tong SYC, Lye DC, Yahav D, Sud A, Robinson JO, Nelson J, et al. Effect of vancomycin or daptomycin with vs without an antistaphylococcal beta-lactam on mortality, bacteremia, relapse, or treatment failure in patients with MRSA bacteremia: a randomized clinical trial. JAMA 2020;323:527–537. https://doi.org/10.1001/jama.2020.0103 329. Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2020;71:1361–1364. https://doi.org/10.1093/cid/ciaa303 330. Fowler VG Jr, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006;355:653–665. https://doi.org/10.1056/ NEJMoa053783 331. Murray KP, Zhao JJ, Davis SL, Kullar R, Kaye KS, Lephart P, et al. Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration >1 mg/L: a matched cohort study. Clin Infect Dis 2013;56:1562–1569. https://doi.org/10.1093/cid/cit112 332. Moore CL, Osaki-Kiyan P, Haque NZ, Perri MB, Donabedian S, Zervos MJ. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study. Clin Infect Dis 2012;54:51–58. https://doi.org/10.1093/cid/cir764 333. Gould IM, Miro JM, Rybak MJ. Daptomycin: the role of high-dose and combination therapy for Gram-positive infections. Int J Antimicrob Agents 2013;42:202–210. https://doi.org/10.1016/j.ijantimicag.2013.05.005 334. Dhand A, Bayer AS, Pogliano J, Yang SJ, Bolaris M, Nizet V, et al. Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding. Clin Infect Dis 2011;53:158–163. https://doi.org/10.1093/cid/cir340 335. Miro JM, Entenza JM, Del Rio A, Velasco M, Castaneda X, Garcia de la Maria C, et al. High-dose daptomycin plus fosfomycin is safe and effective in treating methicillinsusceptible and methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother 2012;56:4511–4515. https://doi.org/10.1128/AAC.06449-11 336. del Rio A, Gasch O, Moreno A, Pena C, Cuquet J, Soy D, et al. Efficacy and safety of fosfomycin plus imipenem as rescue therapy for complicated bacteremia and endocarditis due to methicillin-resistant Staphylococcus aureus: a multicenter clinical trial. Clin Infect Dis 2014;59:1105–1112. https://doi.org/10.1093/cid/ciu580 ESC Guidelines 4029 Downloaded from academic.oup.com/eurheartj/article/44/39/3948/7243107 by guest on 07 October 2026